Urinary leukotriene e4 level profile in various degrees of severity in atopic dermatitis patients in dermatovenereology outpatient clinic
Dr. Soetomo General Hospital, Surabaya: A descriptive study

Meita Ardini Pratamasari, M. Marsoedi Hoetomo, Afif Nurul Hidayati
Dermatovenereology Department, Medical Faculty of Airlangga University/Dr. Soetomo General Hospital Surabaya, East Java, Indonesia

Abstract
Atopic dermatitis (AD) is a chronic, relapsing skin inflammatory disease. Corticosteroid as the cornerstone treatment for AD has some flaw, especially for the chronic recalcitrant AD, since it has side effects and high possibility of rebound. Leukotriene receptor antagonist (LTRA) which has been used for asthma and allergic rhinitis now has been developed for treating AD, based on the similar mechanism of inflammation. Leukotriene (LT) is an inflammatory mediator that is thought to play role in the asthma, allergic rhinitis, and AD. Urinary leukotriene E4 (U-LTE4), the stable metabolite of LT, can be found in urine. This research aims to evaluate the role of LT in various degrees of severity in AD patients by measuring U-LTE4 levels using Enzyme Linked Immunosorbent Assay (ELISA). Twenty two AD patients who were in a flare state and came to the outpatient clinic on April – July 2017 were measured their U-LTE4 levels. The results demonstrated that mean of U-LTE4 levels increases consistently with intensity of the degree of severity, and this finding supports previous study that LT plays role in AD.

Introduction
Atopic dermatitis (AD) is a chronic, relapsing skin inflammatory disease. The prevalence of AD in children is approximately 15-20%, meanwhile prevalence of AD in adults is about 1-3% and both always increase over time. The incidence of AD in Dr. Soetomo General Hospital, Surabaya in 2013-2015 is 0.6% (327 patients) in adults, and 0.62% (366 patients) in children, and also increase in each year. AD still becomes a substantial health problem recently, since the itchy sensation can cause lack of sleep and affect the patient’s quality of life, and disease treatment costs much money. Leukotriene (LT), a potent inflammatory mediator which is derived from arachidonic acid in a pathway that involves 5-lipoxygenase (5-LO), is believed to play a role in AD’s pathogenesis as in asthma’s and allergic rhinitis. Those 3 diseases are known as the atopic triad. One of LT’s classes, cysteinyl leukotriene (Cys-LT), which consists of LTC4, LTD4, and LTE4 is a potent mediator of inflammation. Cys-LT production increases substantially in association with allergic inflammation, likely reflecting the activation of mast cells and eosinophils in the lesional tissues. Urinary leukotriene E4 (U-LTE4) levels increase during asthma, allergic rhinitis, and AD. This finding is supported by previous studies that measured U-LTE4 levels in AD patients, and there was significant correlation between U-LTE4 levels and clinical symptoms (such as degree of severity) and also laboratory marker in AD such as Ig-E serum levels and absolute eosinophil count. Corticosteroid is the cornerstone of AD’s treatment line, but its use in chronic and recalcitrant AD becomes a challenge due to the side effects and high possibility of rebound. Leukotriene receptor antagonist (LTRA) has been used in asthma and allergic rhinitis treatments, and it has been introduced in AD. Some studies revealed that LTRA exhibited positive progression in subjective complaints, skin lesions, and eosinophilic cationic protein. U-LTE4 is the stable end product of LT metabolite, and excreted in the human urine. U-LTE4 is supposed to be reflecting the total body production of LT, because LTC4 and LTD4 are rapidly metabolized into LTE4. Urine examination is a non-invasive method than blood examination so we try to measure the levels in AD patients at our setting and see how the profile is, so that we can consider the use of LTRA in AD treatment.

Materials and Methods
This research was a descriptive study, using cross-sectional method to evaluate U-LTE4 levels in various degrees of severity based on SCORAD index in AD patient. Samples of the study were all AD patients that came to Dermatovenereology Outpatient Clinic Dr. Soetomo General Hospital Surabaya, and were taken consecutively in 4 months (April 2017-July 2017). Inclusion criteria was in a flare or acute condition of AD skin lesion, diagnosed by Williams criteria. Patients who were in corticosteroid treatment in the last 2 weeks, antihistamin treatment in the last 1 week, and other antiinflammation or immunosuppressant treatment include LTRA in the last 4 weeks were excluded from the study. Other exclusion criteria were patients with asthma or allergic rhinitis history, patients who were in the acute phase of allergic or inflammation disease, have kidney disfunction, smokers or in pregnant condition since it can affect the U-LTE4 levels..

Informed consent was obtained from the patients or the parents if the patient was a child. Then the patients diagnosed according to Williams criteria, subjected to history taking, clinical examination, and determined their degrees of severity according to SCORAD index. After that urine sample was taken, then centrifuged and stored in -80°C freezer until the study period had finished. Then all urine samples were measured its U-LTE4 levels by double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) technique, with Human Leukotriene E4 ELISA Kit reagent from Shanghai Crystal Biotech Co., LTD using Humareader® Single. Data are expressed as mean ± SD. No analysis test are performed since this was a descriptive study. Ethical clearance had been approved for this study by the Ethical Committee in the hospital.

[page 119]
Results

This research involved total 22 AD patients in Dermatovenereology Outpatient Clinic General Hospital Surabaya. They were 7 males and 15 females, and their age ranged between 2-51 years old with a mean age of 17.16±13.61 years old. There were 8 patients (36.36%) with mild degree of AD based on SCORAD index, 11 patients (50.00%) with moderate degree, and 3 patients (13.64%) with severe degree. The mean of U-LTE4 levels in total subjects was 24.02±11.02 pg/ml, meanwhile the mean of U-LTE4 levels in mild, moderate, and severe AD based on SCORAD index were 16.43±8.01 pg/ml, 27.45±9.35 pg/ml, and 31.70±15.17 pg/ml, respectively (Figure 1).

The least U-LTE4 level in the samples was 1.2 pg/ml and was found in mild AD group, otherwise the greatest was 41.1 pg/ml and belonged to severe AD group. Table 1 shows that the mean of U-LTE4 levels in each degree of severity are higher in accordance with degree of severity.

Discussion

The purpose of U-LTE4 level measurement is to know the representative of Cys-LT production as inflammatory marker in vivo. Results of this study showed that more severe the degree of severity, the mean of U-LTE4 level were increased. This increasing production of Cys-LT might be caused by increasing immune cells that produce Cys-LT, which are mast cells, basophils, eosinophils, and macrophages. Same observations were reported by Miyoshi et al (1999), Emam et al (2003), Hon et al (2004), and Fathi et al (2007), who concluded that U-LTE4 in moderate and severe degree of AD were significantly higher than the mild degree. They also stated that U-LTE4 levels in AD patients were higher significantly rather than the control subjects. Hishinuma et al also reported that U-LTE4 levels in AD patients were significantly higher than non-AD patient. This study didn’t use controls since we only want to know about the profile of U-LTE4 levels in each degree of severity of AD, whether increase or not.

LT plays role in AD, so the use of LTRA might be considered especially in chronic AD patient who is recalcitrant to any other modalities. Other study that use analytic design still needs to be perform later, so it could demonstrate the relation between U-LTE4 levels and AD degree of severity statistically. Study that compares other laboratoric parameters such as total IgE serum is also needed.

Conclusions

Our findings support other studies that LT plays role in AD, so the use of LTRA might be considered especially in chronic AD patient who is recalcitrant to any other modalities. Other study that use analytic design still needs to be perform later, so it could demonstrate the relation between U-LTE4 levels and AD degree of severity statistically. Study that compares other laboratoric parameters such as total IgE serum is also needed.

Table 1. U-LTE4 levels profile based on degrees of severity in the study subjects (n = 22).

| Degrees of severity | Number (Percentage) | Mean of SCORAD index | Minimum value (pg/ml) | Maximum value (pg/ml) | Mean ± SD (pg/ml) |
|---------------------|---------------------|----------------------|-----------------------|-----------------------|------------------|
| Mild                | 8 (36.36%)          | 20.58±3.02           | 1.2                   | 23.2                  | 16.43±8.01       |
| Moderate            | 11 (50.00%)         | 34.82±4.29           | 10.3                  | 35.8                  | 27.45±9.35       |
| Severe              | 3 (13.64%)          | 58.13±3.35           | 14.2                  | 41.1                  | 31.70±15.17      |
| Total               | 22                  |                      |                       |                       |                  |

Figure 1. U-LTE4 levels distribution based on degrees of severity (SCORAD index) in box-plot.
References

1. Leung DYM, Eichenfield LF, Boguniewicz M. Atopic dermatitis (Atopic eczema). In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2012. p.165-82.

2. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab 2015; 66(suppl 1): 8-16.

3. Fathi G, Saber K, Shaaban F, Fakhry D. Increased urinary leukotriene E4 and its correlation to severity and laboratory markers of atopic dermatitis in children. J Med Sci 2007; 7(2): 216-21.

4. Hishinuma T, Suzuki N, Aiba S, Tagami H, Mizugaki M. Increased urinary leukotriene E4 excretion in patients with atopic dermatitis. Br J Dermatol 2001; 144: 19-23.

5. Liu M, Yokomizo T. The role of leukotrienes in allergic diseases. Allergol Int 2015; 64: 17-26.

6. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors, emerging concepts. Allergy Asthma Immunol Res 2014; 6(4): 288-95.

7. Adamek-Guzik T, Guzik TJ, Czerniawska-Mysik G, Korpanty G, Mastalerz L, Radwan J, et al. Urinary leukotriene levels are increased during atopic eczema/dermatitis syndrome, relation to clinical status. Allergy 2002; 57: 732-6.

8. Mastalerz L, Kumik J. Antileukotriene drugs in the treatment of asthma. Pol Arch Med Wewn 2010; 120(3): 103-8.

9. Eustachio N, D’Erasmo M, Di Leo E, Calogiuri G, Montinaro V, Ferrannini A, et al. The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. Mediators Inflamm (serial online) 2010 [cited on 2016 Aug 30]; [6 screens]. Available from: https://www.hindawi.com/journals/mi/2010/628171/

10. Sala A, Voelkel N, Maclouf J, Murphy RC. Leukotriene E4 elimination and metabolism in normal human subjects. J Biol Chem 1990; 265(35): 21771-8.

11. Haeggström JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 2011; 111: 5866-98.

12. Hon KLE, Leung TF, Ma KC, Li AM, Wong Y, Li CY, et al. Urinary leukotriene E4 correlates with severity of atopic dermatitis in children. Clin Exp Dermatol 2004; 29: 277-81.

13. Emam EK, Salem SAM, Fouad DA. Study of urinary leukotriene E4 in atopic dermatitis: relation to disease severity. Egypt J Pediatr Allergy Immunol 2003; 1(2): 134-9.

14. Mastalerz L, Kumik J. Antileukotriene drugs in the treatment of asthma. Pol Arch Med Wewn 2010; 120(3): 103-8.

15. Eustachio N, D’Erasmo M, Di Leo E, Calogiuri G, Montinaro V, Ferrannini A, et al. The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. Mediators Inflamm (serial online) 2010 [cited on 2016 Aug 30]; [6 screens]. Available from: https://www.hindawi.com/journals/mi/2010/628171/